Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market. The company has struggled to keep up ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from Covid-19 vaccines.

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has earned an average recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

Our fair value estimate is 8.2% lower than Novavax's analyst price target of US$16.43 How far off is Novavax, Inc. (NASDAQ:NVAX) from its intrinsic value? Using the most recent financial data ...

2 strain, which is a more advanced strain compared to JN.1, which the Novavax vaccine is designed to target. Based on the above factors, we expect minimal vaccine sales for the quarter.

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...